AMGN

AMGEN INCeval run

10-K for period ending 2025-12-31gpt-6-luna@none · prompt v4$0.00074.4sfiling on sec.gov ↗

figures

field	value	statement row	printed	SEC
Total revenue	$36.8B	R4 Total revenues	36,751 millions	$36.8B ✓
Operating income	$9.1B	R11 Operating income	9,080 millions	$9.1B ✓
Net income attributable to the company	$7.7B	R17 Net income	7,711 millions	$7.7B ✓
Diluted EPS	$14.23	R20 Diluted	14.23	$14.23 ✓
Cash and cash equivalents	$9.1B	R3 Cash and cash equivalents	9,129 millions	$9.1B ✓
Total assets	$90.6B	R12 Total assets	90,586 millions	$90.6B ✓
Total liabilities	-	not printed on this statement	-	-
Total shareholders' equity attributable to the company	$8.7B	R28 Total stockholders’ equity	8,658 millions	$8.7B ✓
Net cash from operating activities	$10.0B	R20 Net cash provided by operating activities	9,958 millions	$10.0B ✓
Net cash from investing activities	-$1.9B	R27 Net cash used in investing activities	(1,943) millions	-$1.9B ✓
Net cash from financing activities	-$10.9B	R35 Net cash (used in) provided by financing activities	(10,859) millions	-$10.9B ✓

checks

assets = liabilities + equity · total assets equals total liabilities and equity
equity excludes minority interests · not applicable: no noncontrolling interest line printed
net income is before preferred dividends · net income is not the after-preferred-dividends line
diluted EPS is for total net income · diluted EPS is for total net income
net income excludes minority interests · not applicable: no noncontrolling interest line printed
cash flows tie to the change in cash · operating + investing + financing (+ FX) equals the net change in cash

management's claims

The one checkable claim in management's discussion matches the statements.

matchesTotal revenue: "Other revenues" changed 14.66%
“Other revenues increased 15% for 2025, primarily driven by higher royalty income.”

trace

0locator (code)0.14s

{
  "tables": 143,
  "exhibits": [],
  "documents": 1
}

{
  "income": {
    "rows": 24,
    "scale": 1000000,
    "score": 49.75,
    "heading": "INC. CONSOLIDATED STATEMENTS OF INCOME Years ended December 31, 2025, 2024 and 2023 (In millions, except per-share data)",
    "tableIndex": 86,
    "runnerUpScore": 32.5
  },
  "balance": {
    "rows": 30,
    "scale": 1000000,
    "score": 51,
    "heading": "anying notes. F-5 AMGEN INC. CONSOLIDATED BALANCE SHEETS December 31, 2025 and 2024 (In millions, except per-share data)",
    "tableIndex": 88,
    "runnerUpScore": 10
  },
  "cashflow": {
    "rows": 39,
    "scale": 1000000,
    "score": 53.5,
    "heading": "g notes. F-7 AMGEN INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Years ended December 31, 2025, 2024 and 2023 (In millions)",
    "tableIndex": 90,
    "runnerUpScore": 10
  }
}

1cash flow agent1.60s · 1453 tokens · $0.0002

{
  "rows": 39,
  "retryHint": null,
  "tableIndex": 90
}

{
  "figures": [
    {
      "note": "This is the operating activities section total after the working-capital changes.",
      "field": "operatingCashFlow",
      "scale": 1000000,
      "value": 9958000000,
      "printed": "9,958",
      "rowIndex": 20,
      "rowLabel": "Net cash provided by operating activities",
      "priorValue": 11490000000,
      "agentPrinted": "9,958",
      "failedChecks": [],
      "priorPrinted": "11,490",
      "groundingMismatch": false
    },
    {
      "note": "This is the net total for investing activities.",
      "field": "investingCashFlow",
      "scale": 1000000,
      "value": -1943000000,
      "printed": "(1,943)",
      "rowIndex": 27,
      "rowLabel": "Net cash used in investing activities",
      "priorValue": -1046000000,
      "agentPrinted": "(1,943)",
      "failedChecks": [],
      "priorPrinted": "(1,046)",
      "groundingMismatch": false
    },
    {
      "note": "This is the net total for financing activities.",
      "field": "financingCashFlow",
      "scale": 1000000,
      "value": -10859000000,
      "printed": "(10,859)",
      "rowIndex": 35,
      "rowLabel": "Net cash (used in) provided by financing activities",
      "priorValue": -9415000000,
      "agentPrinted": "(10,859)",
      "failedChecks": [],
      "priorPrinted": "(9,415)",
      "groundingMismatch": false
    }
  ],
  "statement": "cashflow",
  "tableIndex": 90,
  "priorColumn": 1,
  "currentColumn": 0
}

2balance sheet agent1.73s · 1271 tokens · $0.0002

{
  "rows": 30,
  "retryHint": null,
  "tableIndex": 88
}

{
  "figures": [
    {
      "note": "This is the balance sheet’s cash and cash equivalents line.",
      "field": "cash",
      "scale": 1000000,
      "value": 9129000000,
      "printed": "9,129",
      "rowIndex": 3,
      "rowLabel": "Cash and cash equivalents",
      "priorValue": 11973000000,
      "agentPrinted": "9,129",
      "failedChecks": [],
      "priorPrinted": "11,973",
      "groundingMismatch": false
    },
    {
      "note": "This row prints total assets.",
      "field": "totalAssets",
      "scale": 1000000,
      "value": 90586000000,
      "printed": "90,586",
      "rowIndex": 12,
      "rowLabel": "Total assets",
      "priorValue": 91839000000,
      "agentPrinted": "90,586",
      "failedChecks": [],
      "priorPrinted": "91,839",
      "groundingMismatch": false
    },
    {
      "note": "The statement does not print a separate total liabilities line.",
      "field": "totalLiabilities",
      "scale": 1000000,
      "value": null,
      "printed": null,
      "rowIndex": null,
      "rowLabel": null,
      "priorValue": null,
      "agentPrinted": null,
      "failedChecks": [],
      "priorPrinted": null,
      "groundingMismatch": false
    },
    {
      "note": "This is the statement’s total stockholders’ equity, with no separate noncontrolling-interest total.",
      "field": "totalEquity",
      "scale": 1000000,
      "value": 8658000000,
      "printed": "8,658",
      "rowIndex": 28,
      "rowLabel": "Total stockholders’ equity",
      "priorValue": 5877000000,
      "agentPrinted": "8,658",
      "failedChecks": [],
      "priorPrinted": "5,877",
      "groundingMismatch": false
    }
  ],
  "statement": "balance",
  "tableIndex": 88,
  "priorColumn": 1,
  "currentColumn": 0
}

3income statement agent1.96s · 1397 tokens · $0.0002

{
  "rows": 24,
  "retryHint": null,
  "tableIndex": 86
}

{
  "figures": [
    {
      "note": "This is the company-wide total revenues line.",
      "field": "revenue",
      "scale": 1000000,
      "value": 36751000000,
      "printed": "36,751",
      "rowIndex": 4,
      "rowLabel": "Total revenues",
      "priorValue": 33424000000,
      "agentPrinted": "36,751",
      "failedChecks": [],
      "priorPrinted": "33,424",
      "groundingMismatch": false
    },
    {
      "note": "This row explicitly reports operating income.",
      "field": "operatingIncome",
      "scale": 1000000,
      "value": 9080000000,
      "printed": "9,080",
      "rowIndex": 11,
      "rowLabel": "Operating income",
      "priorValue": 7258000000,
      "agentPrinted": "9,080",
      "failedChecks": [],
      "priorPrinted": "7,258",
      "groundingMismatch": false
    },
    {
      "note": "The statement prints one net income line and no separate noncontrolling-interest attribution.",
      "field": "netIncome",
      "scale": 1000000,
      "value": 7711000000,
      "printed": "7,711",
      "rowIndex": 17,
      "rowLabel": "Net income",
      "priorValue": 4090000000,
      "agentPrinted": "7,711",
      "failedChecks": [],
      "priorPrinted": "4,090",
      "groundingMismatch": false
    },
    {
      "note": "This is the diluted earnings per share row.",
      "field": "epsDiluted",
      "scale": 1,
      "value": 14.23,
      "printed": "14.23",
      "rowIndex": 20,
      "rowLabel": "Diluted",
      "priorValue": 7.56,
      "agentPrinted": "14.23",
      "failedChecks": [],
      "priorPrinted": "7.56",
      "groundingMismatch": false
    }
  ],
  "statement": "income",
  "tableIndex": 86,
  "priorColumn": 1,
  "currentColumn": 0
}

4reconciler (code)0.00s

null

[
  {
    "name": "balance_identity",
    "detail": "total assets equals total liabilities and equity",
    "fields": [
      "totalAssets"
    ],
    "passed": true,
    "skipped": false,
    "statement": "balance"
  },
  {
    "name": "totalEquity_attribution",
    "detail": "no noncontrolling interest line printed",
    "fields": [
      "totalEquity"
    ],
    "passed": true,
    "skipped": true,
    "statement": "balance"
  },
  {
    "name": "netIncome_before_preferred",
    "detail": "net income is not the after-preferred-dividends line",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "epsDiluted_total",
    "detail": "diluted EPS is for total net income",
    "fields": [
      "epsDiluted"
    ],
    "passed": true,
    "skipped": false,
    "statement": "income"
  },
  {
    "name": "netIncome_attribution",
    "detail": "no noncontrolling interest line printed",
    "fields": [
      "netIncome"
    ],
    "passed": true,
    "skipped": true,
    "statement": "income"
  },
  {
    "name": "cash_flow_tie",
    "detail": "operating + investing + financing (+ FX) equals the net change in cash",
    "fields": [
      "operatingCashFlow",
      "investingCashFlow",
      "financingCashFlow"
    ],
    "passed": true,
    "skipped": false,
    "statement": "cashflow"
  }
]

5MD&A claims agent1.81s · 1030 tokens · $0.0001

null

[
  {
    "kind": "percent_change",
    "field": "revenue",
    "quote": "Other revenues increased 15% for 2025, primarily driven by higher royalty income.",
    "scope": "consolidated",
    "actual": 14.663805436337626,
    "reason": "Total revenue: \"Other revenues\" changed 14.66%",
    "claimed": 15,
    "verdict": "consistent",
    "asWritten": "15%",
    "tolerance": 0.5,
    "quoteVerified": true
  }
]

Income statement

table #86 · current period is figure column 1

0	2025	2024	2023
1	Revenues:
2	Product sales	35,148	32,026	26,910
3	Other revenues	1,603	1,398	1,280
4	Total revenues← Total revenue	36,751	33,424	28,190
5	Operating expenses:
6	Cost of sales	12,037	12,858	8,451
7	Research and development	7,272	5,964	4,784
8	Selling, general and administrative	7,050	7,096	6,179
9	Other	1,312	248	879
10	Total operating expenses	27,671	26,166	20,293
11	Operating income← Operating income	9,080	7,258	7,897
12	Other income (expense):
13	Interest expense, net	(2,755)	(3,155)	(2,875)
14	Other income, net	2,651	506	2,833
15	Income before income taxes	8,976	4,609	7,855
16	Provision for income taxes	1,265	519	1,138
17	Net income← Net income attributable to the company	7,711	4,090	6,717
18	Earnings per share:
19	Basic	14.33	7.62	12.56
20	Diluted← Diluted EPS	14.23	7.56	12.49
21	Weighted-average shares used in the calculation of earnings per share:
22	Basic	538	537	535
23	Diluted	542	541	538

Balance sheet

table #88 · current period is figure column 1

0	2025	2024
1	ASSETS
2	Current assets:
3	Cash and cash equivalents← Cash and cash equivalents	9,129	11,973
4	Trade receivables, net	9,570	6,782
5	Inventories	6,225	6,998
6	Other current assets	4,133	3,277
7	Total current assets	29,057	29,030
8	Property, plant and equipment, net	7,913	6,543
9	Intangible assets, net	22,276	27,699
10	Goodwill	18,680	18,637
11	Other noncurrent assets	12,660	9,930
12	Total assets← Total assets	90,586	91,839
13	LIABILITIES AND STOCKHOLDERS’ EQUITY
14	Current liabilities:
15	Accounts payable	2,367	1,908
16	Accrued liabilities	18,523	17,641
17	Current portion of long-term debt	4,599	3,550
18	Total current liabilities	25,489	23,099
19	Long-term debt	50,005	56,549
20	Long-term deferred tax liabilities	1,366	1,616
21	Long-term tax liabilities	2,690	2,349
22	Other noncurrent liabilities	2,378	2,349
23	Contingencies and commitments (see Note 20)
24	Stockholders’ equity:
25	Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding-538.8 shares in 2025 and 536.9 shares in 2024	34,023	33,533
26	Accumulated deficit	(25,107)	(27,590)
27	Accumulated other comprehensive loss	(258)	(66)
28	Total stockholders’ equity← Total shareholders' equity attributable to the company	8,658	5,877
29	Total liabilities and stockholders’ equity	90,586	91,839

Cash flow statement

table #90 · current period is figure column 1

0	2025	2024	2023
1	Cash flows from operating activities:
2	Net income	7,711	4,090	6,717
3	Noncash adjustments to reconcile net income to net cash provided by operating activities:
4	Depreciation, amortization and other	5,167	5,592	4,071
5	Impairment of intangible assets	1,200	159	851
6	Stock-based compensation expense	494	530	431
7	Deferred income taxes	(721)	(1,228)	(1,273)
8	(Gains) losses on equity securities	(2,064)	159	(1,565)
9	Other items, net	149	(177)	(277)
10	Changes in operating assets and liabilities, net of acquisitions:
11	Trade receivables, net	(2,676)	441	(1,015)
12	Inventories	886	2,532	491
13	Other assets	(1,267)	(652)	(564)
14	Accounts payable	428	312	(402)
15	Accrued income taxes, net	(2,068)	(1,011)	(1,031)
16	Long-term tax liabilities	311	(492)	371
17	Accrued liabilities	499	92	953
18	Accrued sales incentives and allowance	2,065	1,194	935
19	Other liabilities	(156)	(51)	(222)
20	Net cash provided by operating activities← Net cash from operating activities	9,958	11,490	8,471
21	Cash flows from investing activities:
22	Cash paid for acquisitions, net of cash acquired	(53)	-	(26,989)
23	Proceeds from sales of marketable securities	-	-	1,123
24	Proceeds from maturities of marketable securities	-	-	550
25	Purchases of property, plant and equipment	(1,858)	(1,096)	(1,112)
26	Other	(32)	50	224
27	Net cash used in investing activities← Net cash from investing activities	(1,943)	(1,046)	(26,204)
28	Cash flows from financing activities:
29	Net proceeds from issuance of debt	-	-	27,777
30	Extinguishment of debt	(683)	(659)	(647)
31	Repayment of debt	(5,000)	(3,600)	(1,454)
32	Repurchases of common stock	-	(200)	-
33	Dividends paid	(5,124)	(4,832)	(4,556)
34	Other	(52)	(124)	(72)
35	Net cash (used in) provided by financing activities← Net cash from financing activities	(10,859)	(9,415)	21,048
36	(Decrease) increase in cash and cash equivalents	(2,844)	1,029	3,315
37	Cash and cash equivalents at beginning of year	11,973	10,944	7,629
38	Cash and cash equivalents at end of year	9,129	11,973	10,944